Table 2.
Correlation between blood parameters and clinicopathological characteristics.
| Characteristic | MLR | NLR | PLR | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Decrease (n=48) | Increase (n=91) | P | Decrease (n=91) | Increase (n=48) | P | Decrease (n=64) | Increase (n=75) | P | |
| Age (years), n (%) | |||||||||
| <65 | 25 (52.1) | 42 (46.2) | 0.506 | 44 (48.4) | 23 (47.9) | 0.961 | 34 (53.1) | 33 (44.0) | 0.283 |
| ≥65 | 23 (47.9) | 49 (53.8) | 47 (51.6) | 25 (52.1) | 30 (46.9) | 42 (56.0) | |||
| Gender, n (%) | |||||||||
| Male | 39 (81.3) | 72 (79.1) | 0.766 | 71 (78.0) | 40 (83.3) | 0.458 | 54 (84.4) | 57 (76.0) | 0.220 |
| Female | 9 (18.7) | 19 (20.9) | 20 (22.0) | 8 (16.7) | 10 (15.6) | 18 (24.0) | |||
| Smoking history | |||||||||
| Never | 11 (22.9) | 24 (26.4) | 0.655 | 26 (28.6) | 9 (18.8) | 0.205 | 14 (21.9) | 21 (28.0) | 0.407 |
| Current/former | 37 (77.1) | 67 (73.6) | 65 (71.4) | 39 (81.2) | 50 (78.1) | 54 (72.0) | |||
| Histology, n (%) | |||||||||
| Squamous | 19 (39.6) | 25 (27.5) | 0.069 | 26 (28.6) | 18 (37.5) | 0.298 | 23 (36.0) | 21 (28.0) | 0.142 |
| Non-squamous* | 21 (43.7) | 58 (63.7) | 56 (61.5) | 23 (47.9) | 31 (48.4) | 48 (64.0) | |||
| NOS | 8 (16.7) | 8 (8.8) | 9 (9.9) | 7 (14.6) | 10 (15.6) | 6 (8.0) | |||
| TNM stage, n (%) | |||||||||
| IIIB-IIIC | 11 (22.9) | 28 (30.8) | 0.327 | 21 (23.1) | 18 (37.5) | 0.072 | 17 (26.6) | 22 (29.3) | 0.717 |
| IV/Recurrence | 37 (77.1) | 63 (69.2) | 70 (76.9) | 30 (62.5) | 47 (73.4) | 53 (70.7) | |||
| PD-L1 expression, n (%) | |||||||||
| TPS≥50% | 14 (29.2) | 21 (23.1) | 0.821 | 27 (29.7) | 8 (16.7) | 0.264 | 17 (26.6) | 18 (24.0) | 0.743 |
| 1%≤TPS ≤ 49% | 16 (33.3) | 29 (31.9) | 30 (33.0) | 15 (31.2) | 23 (35.9) | 22 (29.3) | |||
| TPS<1% | 13 (27.1) | 29 (31.9) | 25 (27.5) | 17 (35.4) | 17 (26.6) | 25 (33.3) | |||
| Unknown | 5 (10.4) | 12 (13.1) | 9 (9.8) | 8 (16.7) | 7 (10.9) | 10 (13.4) | |||
| Radiotherapy | |||||||||
| Yes | 8 (16.7) | 21 (23.1) | 0.377 | 21 (23.1) | 8 (16.7) | 0.377 | 13 (20.3) | 16 (21.3) | 0.883 |
| No | 40 (83.3) | 70 (76.9) | 70 (76.9) | 40 (83.3) | 51 (79.7) | 59 (78.7) | |||
| irAEs | |||||||||
| Yes | 13 (27.1) | 14 (15.4) | 0.097 | 18 (19.8) | 9 (18.8) | 0.884 | 12 (18.7) | 15 (20.0) | 0.853 |
| No | 35 (72.9) | 77 (84.6) | 73 (80.2) | 39 (81.2) | 52 (81.3) | 60 (80.0) | |||
*Non-squamous tumor included adenocarcinoma, lymphoepithelioma-like carcinoma.
MLR, monocyte-to-lymphocyte ratio; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; NOS, not otherwise specified; PD-L1, programmed cell death-Ligand 1; TPS, tumor proportion score; irAEs; immune-related adverse events.